. "1801-1209" . "Cardiovascular system and gliptins"@en . . "Cardiovascular system and gliptins"@en . "11130" . "Inhibitory dipeptidylpeptid\u00E1zy-4, gliptiny, jsou peror\u00E1ln\u00ED antidiabetika s prok\u00E1zanou \u00FA\u010Dinnost\u00ED a bezpe\u010Dnost\u00ED v l\u00E9\u010Db\u011B diabetes mellitus 2. typu. Jednou z hlavn\u00EDch charakteristik t\u00E9to l\u00E9kov\u00E9 skupiny je gluk\u00F3zo-dependentn\u00ED \u00FA\u010Dinek, spojen\u00FD s minim\u00E1ln\u00EDm rizikem hypoglykemi\u00ED, je\u017E mohou v\u00E9st k rozvoji kardiovaskul\u00E1rn\u00EDch komplikac\u00ED. Intenzivn\u00ED a z\u00E1rove\u0148 bezpe\u010Dn\u00E1 terapie hyperglykemie je z\u00E1kladn\u00ED cestou pro sn\u00ED\u017Een\u00ED rizika org\u00E1nov\u00FDch komplikac\u00ED. Na dal\u0161\u00ED sn\u00ED\u017Een\u00ED kardiovaskul\u00E1rn\u00EDho rizika nez\u00E1visle na zlep\u0161en\u00ED metabolick\u00E9 kompenzace p\u0159i terapii gliptiny poukazuje \u0159ada preklinick\u00FDch a dnes ji\u017E i klinick\u00FDch dat. Zda tento p\u0159\u00EDdavn\u00FD p\u0159\u00EDzniv\u00FD \u00FA\u010Dinek bude m\u00EDt klinick\u00FD korel\u00E1t, uk\u00E1\u017E\u00ED dlouhodob\u011Bj\u0161\u00ED prospektivn\u00ED studie, jejich\u017E v\u00FDsledky brzy \u010Dek\u00E1me."@cs . . . . "gliptins; Cardiovascular system"@en . "Dipeptidyl peptidase-4 inhibitors, gliptins, are oral antidiabetic drugs with demonstrated efficacy and safety in the treatment of type 2 diabetes mellitus. One of the main characteristics of this group of drugs is their glucose- -dependent effect, associated with minimum risk of occurrence of episodes of hypoglycaemia that may otherwise result in the development of cardiovascular complications. Intense and simultaneously safe therapy of hyperglycaemia represents the basic mechanism of reducing the risk of organ complications. A growing body of preclinical and recently also clinical results points to further reduction of cardiovascular risk as a result of gliptin therapy that is independent of improved metabolic control. Whether some clinical correlate is associated with this additive favourable effect remains to be shown in future, longer-term prospective studies whose results should be available soon."@en . . "4"^^ . "1"^^ . . "Kardiovaskul\u00E1rn\u00ED syst\u00E9m a gliptiny"@cs . "Kardiovaskul\u00E1rn\u00ED syst\u00E9m a gliptiny"@cs . "Kardiovaskul\u00E1rn\u00ED syst\u00E9m a gliptiny" . "Kardiovaskul\u00E1rn\u00ED syst\u00E9m a gliptiny" . "RIV/00216208:11130/14:10293540!RIV15-MSM-11130___" . "Farmakoterapie" . "24004" . "1" . . "RIV/00216208:11130/14:10293540" . . . "CZ - \u010Cesk\u00E1 republika" . "V" . . . . "1"^^ . "10" . "[161BCF0C635E]" . "Jan\u00ED\u010Dkov\u00E1 \u017D\u010F\u00E1rsk\u00E1, Denisa" . "Inhibitory dipeptidylpeptid\u00E1zy-4, gliptiny, jsou peror\u00E1ln\u00ED antidiabetika s prok\u00E1zanou \u00FA\u010Dinnost\u00ED a bezpe\u010Dnost\u00ED v l\u00E9\u010Db\u011B diabetes mellitus 2. typu. Jednou z hlavn\u00EDch charakteristik t\u00E9to l\u00E9kov\u00E9 skupiny je gluk\u00F3zo-dependentn\u00ED \u00FA\u010Dinek, spojen\u00FD s minim\u00E1ln\u00EDm rizikem hypoglykemi\u00ED, je\u017E mohou v\u00E9st k rozvoji kardiovaskul\u00E1rn\u00EDch komplikac\u00ED. Intenzivn\u00ED a z\u00E1rove\u0148 bezpe\u010Dn\u00E1 terapie hyperglykemie je z\u00E1kladn\u00ED cestou pro sn\u00ED\u017Een\u00ED rizika org\u00E1nov\u00FDch komplikac\u00ED. Na dal\u0161\u00ED sn\u00ED\u017Een\u00ED kardiovaskul\u00E1rn\u00EDho rizika nez\u00E1visle na zlep\u0161en\u00ED metabolick\u00E9 kompenzace p\u0159i terapii gliptiny poukazuje \u0159ada preklinick\u00FDch a dnes ji\u017E i klinick\u00FDch dat. Zda tento p\u0159\u00EDdavn\u00FD p\u0159\u00EDzniv\u00FD \u00FA\u010Dinek bude m\u00EDt klinick\u00FD korel\u00E1t, uk\u00E1\u017E\u00ED dlouhodob\u011Bj\u0161\u00ED prospektivn\u00ED studie, jejich\u017E v\u00FDsledky brzy \u010Dek\u00E1me." .